Neural Regeneration Research. Aug/24/2013; 8(24): 2256-2265

PMID: 25206535

doi: 10.3969/j.issn.1673-5374.2013.24.005

The mechanism of astragaloside IV promoting sciatic nerve regeneration

Abstract

3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosyl-cycloastragenol (astragaloside IV), the main active component of the traditional Chinese medicine astragalus membranaceus, has been shown to be neuroprotective. This study investigated whether astragaloside IV could promote the repair of injured sciatic nerve. Denervated sciatic nerve of mice was subjected to anastomosis. The mice were intraperitoneally injected with 10, 5, 2.5 mg/kg astragaloside IV per day for 8 consecutive days. Western blot assay and real-time PCR results demonstrated that growth-associated protein-43 expression was upregulated in mouse spinal cord segments L_4–6 after intervention with 10, 5, 2.5 mg/kg astragaloside IV per day in a dose-dependent manner. Luxol fast blue staining and electrophysiological detection suggested that astragaloside IV elevated the number and diameter of myelinated nerve fibers, and simultaneously increased motor nerve conduction velocity and action potential amplitude in the sciatic nerve of mice. These results indicated that astragaloside IV contributed to sciatic nerve regeneration and functional recovery in mice. The mechanism underlying this effect may be associated with the upregulation of growth-associated protein-43 expression.

Research Highlights

(1)Astragaloside IV, the main component of the traditional Chinese medicine astragalus membranaceus, has been shown to exert neuroprotective effects, but studies regarding this compound are limited.
(2)This study assumed that astragaloside IV promoted the repair of sciatic nerve injury, and observed whether its mechanism of action was influenced by growth-associated protein-43 expression.
(3)Astragaloside IV accelerated nerve myelin sheath growth in mice with sciatic nerve injury, increased the diameter and number of myelinated nerve fibers, and elevated and accelerated pheral nerve regeneration and functional reconstruction by upregulating growth-associated tein-43 expression.

INTRODUCTION

The outcomes of conventional surgical and conservative medical treatment for peripheral nerve injury have been disappointing[1 2]. Recent studies confirmed that natural medicine can stimulate nerve growth factor expression after nerve injury, and promote peripheral nerve regeneration and functional recovery[2 3 4 5 6 7 8 9]. These results indicated that natural medicine could be a new method for promoting the repair of peripheral nerve injury.

3-O-beta-D-xylopyranosyl-6-O-beta-D-glucop yranosyl-cycloastragenol, astragaloside IV, is a major active component of the traditional Chinese medicine astragalus membranaceus, and its structure is shown in Figure 1.

Figure 1

Chemical structure of astragaloside IV.

Astragaloside IV can inhibit inflammation, oxidation, and apoptosis, and exerts immunoregulatory effects. This compound also protects the heart, intestines and stomach[10 11]. In the central nervous system, astragaloside IV has contributed to nerve repair after cerebral ischemia/reperfusion injury[8], accelerated axon growth in mouse hippocampi, prevented neuronal atrophy and memory loss[12], and suppressed spontaneous synaptic conduction and Ca²⁺ oscillation in hippocampal neurons[10]. Astragaloside IV also protected primary cultured nigral cells against 6-hydro-xydopamine-induced injury[13]. Additionally, astragaloside IV combined with ginsenoside prevented oxidative damage of adult PC 12 cells and protected mitochondrial membrane potential[14]. In the peripheral nervous system, astragaloside IV also can protect and promote peripheral nerve regeneration[1 2].

Neural growth-associated protein 43 guides neuronal growth and branching during neural development and regeneration, possibly inducing changes in the presynaptic membrane and neurotransmitter release, thus promoting long-term potentiation, spatial memory and learning[15 16 17].

Previous studies suggested that growth-associated protein 43 expression gradually increased in the corpus striatum and ipsilateral ischemic cortex after cerebral ischemia/reperfusion. This increase in the ischemic hemisphere occurred to different extents[16 17 18 19 20 21 22 23 24 25 26 27].

This study supposed that astragaloside IV contributed to the repair of sciatic nerve injury, and its mechanisms were associated with the upregulation of growth-associated protein 43 that is involved in axonal regeneration. This study observed the effects of astragaloside IV on peripheral nerve regeneration and functional recovery in a mouse model of sciatic nerve injury, and also determined the expression of growth-associated protein 43 during peripheral nerve regeneration. The mechanism of action of astragaloside IV on peripheral nerve regeneration and functional recovery was also investigated.

RESULTS

Quantitative analysis of experimental animals

A total of 169 BALB/c mice were used in the study, with nine dying during anesthesia. The remaining 160 mice were used to establish a model of sciatic nerve injury by denervating the left sciatic nerve. After model induction, mice were equally and randomly assigned to model, high-, moderate-, or low-dose astragaloside IV groups, and were intraperitoneally injected with saline 1 mL, or 10, 5, or 2.5 mg/kg astragaloside IV per day, respectively, for 1, 2, 4, and 8 consecutive weeks. Ten mice from each group were used at each time point. One hundred and sixty mice were included in the final analysis.

Astragaloside IV accelerated the recovery of sciatic nerve function in mice

Electrophysiology results suggested that at 1, 2, 4, and 8 weeks after sciatic nerve injury, sciatic nerve conduction amplitude and velocity were gradually increased in each group. The recovery of sciatic nerve was significantly better in the high- and moderate-dose astragaloside IV groups than that in the low-dose astragaloside IV and model groups (P < 0.05; Tables 1, 2).

Table 1

Effects of astragaloside IV on sciatic nerve conduction amplitude (mV) in mice with sciatic nerve injury

Table 2

Effects of astragaloside IV on motor nerve conduction velocity (m/s) in mice with sciatic nerve injury

Astragaloside IV upregulated growth-associated protein 43 mRNA expression in spinal cord segments L_4–6 of mice with sciatic nerve injury

Real-time PCR revealed that growth-associated protein 43 mRNA contents gradually increased in corresponding spinal cord segments in the low-dose astragaloside IV and model groups. This mRNA expression peaked at 4 weeks after sciatic nerve injury, and decreased at 8 weeks. Compared with the low-dose astragaloside IV and model groups, growth-associated protein 43 mRNA expression significantly increased in the high-dose and moderate-dose astragaloside IV groups (P < 0.05). Growth-associated protein 43 expression peaked at 1 week following sciatic nerve injury, and decreased at 8 weeks. The upregulation of growth-associated protein 43 mRNA expression was most significant in the high-dose astragaloside IV group (Figure 2).

Figure 2

Effects of astragaloside IV on growth-associated protein 43 (GAP-43) mRNA expression in spinal cord segments L_4–6 in mice with sciatic nerve injury.

High-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5 and 2.5 mg/kg per day, respectively. The measurement data were expressed as the Ct ratio of growth-associated protein 43/glyceraldehyde-phosphate dehydrogenase (GAPDH). Data are expressed as mean ± SD. Ten mice from each group were used at each time point. ^aP < 0.05, vs. model group; ^bP < 0.05, vs. low-dose astragaloside IV group; ^cP < 0.05, vs. moderate-dose astragaloside IV group. One-way analysis of variance and least significant difference t-test were used.

Astragaloside IV upregulated growth-associated protein 43 protein expression in spinal cord segments L_4–6 of mice with sciatic nerve injury

Western blot assay results revealed that growth-associated protein 43 protein expression reached a peak in each group at 1 week after sciatic nerve injury, and then gradually decreased. Compared with the model group, growth-associated protein 43 protein expression was significantly higher in the high-dose and moderate-dose astragaloside IV groups at various time points (P < 0.05). Moreover, growth-associated protein 43 protein expression was also significantly upregulated in the low-dose astragaloside IV group at 1, 2 and 4 weeks after injury (P < 0.05). No significant difference in growth-associated protein 43 protein expression was detectable between the low-dose astragaloside IV group and model group at 8 weeks. Growth-associated protein 43 protein expression was significantly greater in the high-dose and moderate-dose astragaloside IV groups than that in the low-dose astragaloside IV group at various time points after injury (P < 0.05), and the upregulation was most significant in the high-dose astragaloside IV group (Figure 3, Table 3).

Figure 3

Effects of astragaloside IV on growth-associated protein 43 protein expression in spinal cord segments L_4–6 in mice with sciatic nerve injury.

10, 5 and 2.5 mg/kg per day astragaloside IV were used. Compared with the model group (injected with saline, D), high, moderate and low-dose astragaloside IV (A, B, C) can upregulate growth-associated protein 43 protein expression in spinal cord segments L_4–6 in mice with sciatic nerve injury.

Table 3

Effects of astragaloside IV on growth-associated protein 43 protein expressions in spinal cord segments L_4–6 in mice at various time points after sciatic nerve injury

Astragaloside IV promoted the remyelination of sciatic nerve in model mice

Luxol fast blue staining revealed the structure of the myelin sheath around mouse sciatic nerves. Function of the sciatic nerve was mostly recovered at 8 weeks after sciatic nerve injury; therefore, sciatic nerve samples were stained with Luxol fast blue at 8 weeks after injury to observe the effects of astragaloside IV on the sciatic nerve myelin sheath. The sciatic nerve myelin sheath was found to be regular and uniform, with an obvious outline in the high-dose and moderate-dose astragaloside IV groups (Figure 4A, B). By contrast, the sciatic nerve myelin sheath was irregular, with a clear outline in the low-dose astragaloside IV group. Furthermore, fibrous connective tissue hyperplasia was visible among nerve bundles (Figure 4C). The sciatic nerve myelin sheath was irregular, and fibrous connective tissue hyperplasia was also apparent in the model group (Figure 4D). Compared with the model group, sciatic nerve myelin sheath regeneration was clearly promoted in the high-dose and moderate-dose astragaloside IV groups, especially in the high-dose astragaloside IV group.

Figure 4

Effects of astragaloside IV on the structure of injured sciatic nerve in mice (Luxol fast blue staining, × 400, transverse section).

(A) High density myelin sheath of the sciatic nerve was observed in the high-dose astragaloside IV group (10 mg/kg per day). (B) Sky blue staining is seen in the high-density myelin sheath in the moderate-dose astragaloside IV group (5 mg/kg per day). The nerve myelin sheath was arranged irregularly in the low-dose astragaloside IV group (2.5 mg/kg per day) (C) and model group (D). At 8 weeks after sciatic nerve injury, the sciatic nerve myelin sheath was stained blue. Unstained axons and a white background were also observed. Arrows indicate stained myelin sheath.

The number and diameter of myelinated nerve fibers were significantly higher in the high-, moderate- and low-dose astragaloside IV groups when compared with the model group (P < 0.05). The number and diameter of myelinated nerve fibers were significantly greater in the high-dose and moderate-dose astragaloside IV groups compared with the low-dose astragaloside IV group (P < 0.05). No significant difference in the number and diameter of myelinated nerve fibers was detected between the high-dose and moderate-dose astragaloside IV groups (Table 4).

Table 4

Effects of astragaloside IV on the number and diameter of myelinated nerve fibers in mice at 8 weeks after sciatic nerve injury

DISCUSSION

Astragaloside IV promotes neural regeneration or prevents neural injury through various mechanisms[1 9 10 11 12 13 14]. Growth-associated protein 43 is highly expressed in individual neurons during development and adult cerebral hippocampal neurons[28 29 30 31]. Growth-associated protein 43 is a sensitive specific molecular marker present during nerve injury and repair, and plays an important role in nerve growth, development and regeneration[32 33 34 35]. During axon regeneration in the central nervous system, growth-associated protein 43 expression is significantly upregulated, which clearly promotes neural regeneration and repair[36 37 38 39 40 41]. Thus, this study established a mouse model of sciatic nerve injury, and observed the effects of astragaloside IV on peripheral nerve regeneration, functional recovery, and growth-associated protein 43 expression during peripheral nerve regeneration.

In this study, Luxol fast blue staining was used to determine the changes in sciatic nerve myelin sheath structure, and results revealed that high-dose and moderate-dose astragaloside IV accelerated the growth of myelin sheath surrounding injured sciatic nerve, increased the number and diameter of myelinated nerve fibers, contributed to neural regeneration and structural reconstruction, and elevated the quality of regenerating nerve. Electrophysiological detection suggested that regenerating sciatic nerve had good structure at 8 weeks, showing good motor nerve conduction velocity and action potential amplitude. Results of electrophysiological detection completely coincided with the results of Luxol fast blue staining.

Growth-associated protein 43 expression was lower in spinal cord segments L_4–6 from normal Balb/c mice[42 43 44 45 46 47], active in growing neuronal axons, and strongly associated with neuronal axon growth[34 48 49 50]. In the present study, western blot assay and real-time PCR results demonstrated that growth-associated protein 43 expression was activated and highly expressed in corresponding spinal cord segments of mice with sciatic nerve injury. Growth-associated protein 43 expression was significantly greater in the high-dose and moderate-dose astragaloside IV groups than in the low-dose astragaloside IV group and model group within 4 weeks. These results suggested that high-dose and moderate-dose astragaloside IV apparently upregulated growth-associated protein 43 expression in regenerating nerve tissues. Moreover, this promoting effect could last at least 4 weeks. At 8 weeks, growth-associated protein 43 expression was identical between high- and moderate-dose astragaloside IV groups and the model group. However, astragaloside IV promoted the upregulation of growth-associated protein 43 expression for up to 4 weeks, so the structure and function of the sciatic nerve in the astragaloside IV groups were better than those in the model group. Gerin et al[37] confirmed that endogenous repair genes including growth-associated protein 43 are persistently expressed for 12 weeks following spinal cord injury. Therefore, this study presumed that growth-associated protein 43 was probably persistently expressed in the 4 weeks following insult in each group[46], which contributed to the regeneration and repair of sciatic nerve, but was further stimulated by the treatment with astragaloside IV.

Appropriate expression of growth-associated protein 43 promotes neural recovery and regeneration, but excessive expression can contribute to inflammatory reaction and scar formation, and suppress myelin sheath growth[2 51 52 53 54 55 56 57]. In this study, upregulation of growth-associated protein 43 expression promoted peripheral nerve regeneration, indicating that high-dose and moderate-dose astragaloside IV was in an appropriate range, all of which contributed to growth-associated protein 43 expression and exerted an accelerated regulatory effect on neural regeneration. In the high-dose and moderate-dose astragaloside IV groups, growth-associated protein 43 mRNA maintained a stable high expression at 1, 2 and 4 weeks, and showed a decreased expression at 8 weeks. Growth-associated protein 43 protein expression peaked at 1 week, and then gradually diminished. The expression of mRNA and protein showed a certain asynchrony, indicating that there was endogenous translational control or post-translational control. High levels of growth-associated protein 43 protein may have been upregulated to avoid neural injury. The promoting effect of astragaloside IV on neural regeneration possibly has multiple molecular mechanisms[1 8 9 10 13 14]. This study also presumed that astragaloside IV had a persistent promoting effect (at least for 4 weeks) on activation of growth-associated protein 43 in the spinal cord segments L_4–6 after sciatic nerve injury, resulting in a positive regulatory effect on peripheral nerve regeneration and functional recovery.

In summary, astragaloside IV elevated and accelerated peripheral nerve regeneration and functional reconstruction, which is associated with its regulatory effect on growth-associated protein 43 expression.

MATERIALS AND METHODS

Design

A randomized, controlled animal study.

Time and setting

Experiments were performed at the National Key Laboratory, Central Laboratory, China-Japan Union Hospital, Jilin University, China from November 2010 to May 2011.

Materials

Animals

Healthy clean male BALB/c mice, aged 8 weeks old and weighing 20 ± 2 g, were provided by the Experimental Animal Center, School of Basic Medicine, Jilin University, China (license No. SCXK (Ji) 2007-0001). The protocols were conducted in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals, formulated by Ministry of Science and Technology of China[58].

Drugs

Astragaloside IV was purchased from the National Institute for Food and Drug Control in China. Astragaloside IV was dissolved using dimethyl sulfoxide to create a stock solution of 10 g/L, and diluted with saline to working concentrations[59].

Methods

Preparation of a mouse model of sciatic nerve injury

BALB/c mice were intraperitoneally anesthetized with 1% sodium thiopental, and fixed in the prone position. Under aseptic conditions, a 2-cm longitudinal incision was made at the posterior thigh of the left hindlimb. The sciatic nerve was exposed at the inferior border of the piriform muscle. The trunk and surrounding tissues of the sciatic nerve were bluntly separated using a glass needle. The sciatic nerve was completely denervated at 0.5 cm below the ischial tuberosity. Ten minutes later, the sciatic nerve was anastomosed using 11/0 sutures under a 12-fold microscope (Surgery Microinstrument Factory, Zhenjiang, Jiangsu Province, China), and muscle and skin were separately sutured closed (Figure 5)[60].

Figure 5

Injured sciatic nerve of a mouse.

Arrow shows sciatic nerve and the denervated site.

Drug intervention

The dose of astragaloside IV was consistent with the amount of original astragaloside IV administered clinically, and was found to be equivalent to the intraperitoneal dose of 5 mg/kg per day. This amount was considered a moderate dose. 10 mg/kg per day and 2.5 mg/kg per day were considered high and low doses, respectively. Administration was performed immediately after model induction. Mice in the high-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5, 2.5 mg/kg astragaloside IV per day[59] (dissolved in dimethyl sulfoxide, diluted in saline), respectively. Mice in the model group were given 1 mL/d saline. Drug administration was consecutively performed until experiments were complete or samples were collected.

Neuroeletrophysiology for the recovery of sciatic nerve function in mice after astragaloside IV intervention

Bilateral sciatic nerves of mice were investigated using a Medtronic Keypoint electromyograph machine (Medtronic Corporation, Minneapolis, MN, USA) at 1, 2, 4 and 8 weeks after model establishment. Room temperature was maintained at 24°C. Animals were intraperitoneally anesthetized with 1% sodium triopental. After disinfection, the sciatic nerve was exposed in a prone position. Concentric needle electrodes were placed in the mouse soleus muscle as a recording electrode (M point). A ground electrode was placed in the mouse tail. Super-strong stimuli (current 10 mA) were given at the level of the ischial tuberosity proximal to the anastomotic stoma (P point) and the branch of the distal sciatic nerve (D point) using double head stimulating electrodes (the distance between the two electrodes was 2 mm). The distance between the electrodes P-D was measured using a vernier caliper to calculate the difference of action potential latency, which represents the time for the nerve impulse to traverse the two points. Motor nerve conduction velocity of sciatic nerve was equal to the distance of P-D/difference of action potential latency (m/s). Simultaneously, motor nerve action potential amplitude of the sciatic nerve (mV) was measured using the vernier caliper.

Sample collection

A total of 10 mice from each group were obtained at 1, 2, 4 and 8 weeks after injury. They were intraperitoneally anesthetized with 1% sodium thiopental. A median incision was made at the posterior spine, and the vertebral canal was opened with rongeur forceps. Spinal cord segments L_4–6, connected to the sciatic nerve, were intact and exposed (Figure 6). Spinal cord segments L_4–6 from the injured side were obtained, marked and rapidly immersed in liquid nitrogen for western blot assay and real-time PCR. In addition, sciatic nerve trunk from anastomotic stoma (0.5 cm, including the anastomotic stoma) to the distal end was obtained and fixed in 10% neutral formalin over 72 hours, dehydrated through a graded alcohol series, embedded in paraffin, and sliced into 2-μm-thick sections.

Figure 6

Morphology of mouse spinal cord segments L_4–6 after high-dose astragaloside IV intervention at 8 weeks following sciatic nerve injury.

Arrows show anastomotic stoma (1) and distal nerve trunk (2).

Real-time PCR for growth-associated protein 43 mRNA expression in spinal cord segments L_4–6 of mice

Growth-associated protein 43 and reduced glyceralde-hyde-phosphate dehydrogenase (GAPDH) primers were designed using Beacon designer 7 software (PREMIER Biosoft, Palo Alto, CA, USA) in accordance with NCBI Genbank (http://www.ncbi.nlm.nih.gov/genbank/). Primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd., Shanghai, China. Primer sequences are listed in Table 5.

Table 5

Primer sequences of GAP-43 and GAPDH

Spinal cord segments L_4–6 were obtained at various time points. Total RNA was extracted using an extraction kit [Sangon Biotech (Shanghai) Co., Ltd.] using the TRIzol reagent method. First-strand cDNA was synthesized with a reverse transcription kit (M-MLV RTase Kit, Promega, Beijing, China), and cDNA was synthesized further. cDNA served as a template. Real-time PCR was used to amplify growth-associated protein 43 in the spinal cord segments L_4–6. A 2 × SYBR real-time quantitative PCR kit was purchased from Roche (Beijing, China). Reaction conditions were as follows: 95°C for 30 seconds, 58°C for 60 seconds, and 72°C for 60 seconds, 40 cycles in total. GAPDH served as an internal reference. Stratagene Mx3000P Real-Time QPCR System (Agilent Technologies, Beijing, China) was used to detect the Ct values of growth-associated protein 43 and internal reference gene (Stratagene MxPro QPCR Software, Agilent Technologies, Beijing, China). Relative mRNA expression of growth-associated protein 43/GAPDH was calculated.

Western blot assay for growth-associated protein 43 protein expression in the spinal cord segments L_4–6 of mice

Spinal cord segments L_4–6 were obtained at various time points and triturated in a mortar with RIPA lysis buffer. Total protein was extracted with an extraction kit (Beyotime Institute of Biotechnology, Nanjing, Jiangsu Province, China). After adding loading buffer, samples were boiled in water for 15 minutes. After centrifugation, the supernatant was obtained and electrophoresed on 12% sodium dodecyl sulfate-polyacrylamide gel, and electrotransferred onto polyvinylidene fluoride membrane using the wet method[9]. The membrane was immersed in rabbit anti-mouse growth-associated protein 43 or GAPDH antibody (1:1 000; Roche, Shanghai, China) at 4°C overnight. After four washes with 0.01 mol/L PBS (each for 5 minutes), the membrane was incubated in goat anti-rabbit IgG (1:10 000; Roche) at room temperature for 1 hour. After four washes with 0.01 mol/L PBS (each for 5 minutes), the membrane was visualized in accordance with the instructions from the enhanced chemiluminescence kit (Roche). X-Ray film was exposed and analyzed using a gel image processing system (UVP EC3 600 Imaging System, UVP LLC, Upland, CA, USA). Gray values of target blots were analyzed with an image processing system using VisionWorksLS software, and relative gray values (growth-associated protein-43/GAPDH) were calculated.

Luxol fast blue staining for the diameter and number of myelinated nerve fibers in mouse sciatic nerve

Sciatic nerve trunk from the anastomotic stoma (0.5 cm, including the anastomotic stoma) to the distal end was obtained and fixed in 10% neutral formalin for > 72 hours, dehydrated through a graded alcohol series, embedded in paraffin, and sliced into sections of 3.0 μm. After deparaffinization, the samples were immersed in Luxol fast blue staining solution at 60°C for 12 hours, then subsequently immersed in 95% alcohol for 5 minutes, and treated with 0.05% lithium carbonate for 15 seconds. After a wash with 70% alcohol, the samples were washed with distilled water, dehydrated, permeabilized, mounted, observed and photographed with a light microscope (Eclipse TE-2000-U, Nikon, equipped with an attached digital camera SXM1200F, Tokyo, Japan). The diameter and number of myelinated nerve fibers were determined using an image scanner (Olympus, Tokyo, Japan).

Statistical analysis

Measurement data were expressed as mean ± SD and analyzed using SPSS 17.0 software (SPSS, Chicago, IL, USA). Mean difference among multiple groups was compared using one-way analysis of variance. Paired comparison of intergroup mean difference was performed using least significant difference t-test. A value of P < 0.05 was considered statistically significant.

Footnotes

Conflicts of interest: None declared.

Ethical approval: This study was approved by the Animal Ethics Committee of Jilin University in China.

(Reviewed by Apricò K, Haase R, Li DF, Yin WT)

(Edited by Wang J, Qiu Y, Li CH, Song LP, Liu WJ, Zhao M)

References

1. YuJZhangYSunSInhibitory effects of astragaloside IV on diabetic peripheral neuropathy in ratsCan J Physiol Pharmacol2006846579587[PubMed][Google Scholar]
2. ChengCYYaoCHLiuBSThe role of astragaloside in regeneration of the peripheral nerve systemJ Biomed Mater Res A2006763463469[PubMed][Google Scholar]
3. QiuDZhaoGAokiYImmunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activationJ Biol Chem1999274191344313450[PubMed][Google Scholar]
4. XueBJiaoJZhangLTriptolide upregulates NGF synthesis in rat astrocyte culturesNeurochem Res200732711131119[PubMed][Google Scholar]
5. YeMXieWDLeiFBrazilein, an important immunosuppressive component from Caesalpinia sappan LInt Immunopharmacol200663426432[PubMed][Google Scholar]
6. YangEBZhaoYNZhangKDaphnetin, one of coumarin derivatives, is a protein kinase inhibitorBiochem Biophys Res Commun19992603682685[PubMed][Google Scholar]
7. TohdaCTamuraTMatsuyamaSPromotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicusBr J Pharmacol20061495532541[PubMed][Google Scholar]
8. YinYYLiWPGongHLProtective effect of astragaloside on focal cerebral ischemia/reperfusion injury in ratsAm J Chin Med2010383517527[PubMed][Google Scholar]
9. ZhangZGWuLWangJLAstragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS productionMol Cell Biochem20123641-2209216[PubMed][Google Scholar]
10. ZhuSQQiLRuiYFAstragaloside IV inhibits spontaneous synaptic transmission and synchronized Ca2⁺ oscillations on hippocampal neuronsActa Pharmacol Sin20082915764[PubMed][Google Scholar]
11. ZhangCWangXHZhongMFMechanisms underlying vasorelaxant action of astragaloside IV in isolated rat aortic ringsClin Exp Pharmacol Physiol2007345-6387392[PubMed][Google Scholar]
12. TohdaCTamuraTMatsuyamaSPromotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicusBr J Pharmacol20061495532541[PubMed][Google Scholar]
13. ChanWSDurairajanSSLuJHNeuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell cultureNeurochem Int2009556414422[PubMed][Google Scholar]
14. HuangXPLiuXDDengCQEffects of the combination of active component extracts from Astragalus membranaceus and Panax notoginseng on apoptosis, reactive oxygen species and mitochondrial membrane potential of PC12 cells with oxidative injuryZhong Xi Yi Jie He Xue Bao2012101011271134[PubMed][Google Scholar]
15. ZhangZZhangHDuBNeonatal handling and environmental enrichment increase the expression of GAP-43 in the hippocampus and promote cognitive abilities in prenatally stressed rat offspringNeurosci Lett2012522115[PubMed][Google Scholar]
16. DennyJBMolecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43Curr Neuropharmacol200644293304[PubMed][Google Scholar]
17. KorshunovaIMosevitskyMRole of the growth-associated protein GAP-43 in NCAM-mediated neurite outgrowthAdv Exp Med Biol2010663169182[PubMed][Google Scholar]
18. ZhengGYShiWQChenXDInfluence of ilexonin A on the expression of bFGF, GAP-43 and neurogenesis after cerebral ischemia-reperfusion in ratsYao Xue Xue Bao201146910651071[PubMed][Google Scholar]
19. HouDRShadikeSDengJFEffect of willed movement therapy on the expression of neurotrophin 3 and growth-associated protein 43 in rats with cerebral ischemia reperfusionNan Fang Yi Ke Da Xue Xue Bao201131814011404[PubMed][Google Scholar]
20. ZhouZWYangJYangQDEffects of tetrahydroxystilbene glucoside on nerve growth factor and growth associated protein in rats after cerebral ischemia-reperfusionZhong Yao Cai201033711201124[PubMed][Google Scholar]
21. NiuLZhouJHuangYdb-Cyclic adenosine monophosphate promotes axon regeneration and motor function recovery in cerebral ischemia-reperfusion ratsNeurol India2010582195200[PubMed][Google Scholar]
22. YangJZhouZYangQNeuroprotective mechanism of tetrahydroxystilbene glucoside on rats after cerebral schemia-reperfusionZhong Nan Da Xue Xue Bao Yi Xue Ban2010354321328[PubMed][Google Scholar]
23. DijkFBergenAAKamphuisWGAP-43 expression is upregulated in retinal ganglion cells after ischemia/reperfusion-induced damageExp Eye Res2007845858867[PubMed][Google Scholar]
24. JuWKGwonJSParkSJGrowth-associated protein 43 is up-regulated in the ganglion cells of the ischemic rat retinaNeuroreport2002136861865[PubMed][Google Scholar]
25. LiYJiangNPowersCNeuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1 immunoreactivity after focal cerebral ischemia in ratsStroke199829919721980[PubMed][Google Scholar]
26. LiYBickelKDImMJEffects of deferoxamine on ischemia/reperfusion injury after peripheral nerve compressionAnn Plast Surg1996364365369[PubMed][Google Scholar]
27. TagayaMMatsuyamaTNakamuraHIncreased F1/GAP-43 mRNA accumulation in gerbil hippocampus after brain ischemiaJ Cereb Blood Flow Metab199515611321136[PubMed][Google Scholar]
28. BuizzaLPrandelliCBoniniSAConformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expressionCell Death Dis20134e484[PubMed][Google Scholar]
29. ZhangWLiZThe effects of target skeletal muscle cells on dorsal root ganglion neuronal outgrowth and migration in vitroPLoS One201381e52849[PubMed][Google Scholar]
30. ZhangHFanSExpression and significance of growth-associated protein 43 in a rat model of intervertebral disc inflammationZhongguo Xiu Fu Chong Jian Wai Ke Za Zhi2012261214351441[PubMed][Google Scholar]
31. TułodzieckaKCzeredysMNałęzKAPalmitoylcarnitine affects localization of growth associated protein GAP-43 in plasma membrane subdomains and its interaction with Gα(o) in neuroblastoma NB-2a cellsNeurochem Res2013383519529[PubMed][Google Scholar]
32. WuFMiaoXChenJDown-regulation of GAP-43 by inhibition of caspases-3 in a rat model of neuropathic painInt J Clin Exp Pathol201259948955[PubMed][Google Scholar]
33. ShenYMeiriKGAP-43 dependency defines distinct effects of netrin-1 on cortical and spinal neurite outgrowth and directional guidanceInt J Dev Neurosci20133111120[PubMed][Google Scholar]
34. MoritaSMiyataSSynaptic localization of growth-associated protein 43 in cultured hippocampal neurons during synaptogenesisCell Biochem Funct2012[Google Scholar]
35. GrynspanDGiassiACCadonicRGrowth-associated protein-43 (GAP-43) expression in ganglionic and aganglionic colonPediatr Dev Pathol2012[Google Scholar]
36. ZaccariaKJMcCaslandJSEmergence of layer IV barrel cytoarchitecture is delayed in somatosensory cortex of GAP-43 deficient mice following delayed development of dendritic asymmetrySomatosens Mot Res20122937788[PubMed][Google Scholar]
37. GerinCGMaduekeICPerkinsTCombination strategies for repair, plasticity, and regeneration using regulation of gene expression during the chronic phase after spinal cord injurySynapse2011651212551281[PubMed][Google Scholar]
38. KorshunovaIMosevitskyMRole of the growth-associated protein GAP-43 in NCAM-mediated neurite outgrowthAdv Exp Med Biol2010663169182[PubMed][Google Scholar]
39. ManasseroGRepettoIECobianchiSRole of JNK isoforms in the development of neuropathic pain following sciatic nerve transection in the mouseMol Pain2012839[PubMed][Google Scholar]
40. ZhangZZhangHDuBNeonatal handling and environmental enrichment increase the expression of GAP-43 in the hippocampus and promote cognitive abilities in prenatally stressed rat offspringNeurosci Lett2012522115[PubMed][Google Scholar]
41. XingYHLengYFWangSXClonidine and dexmedetomidine's effect on the altered expressions of growth associated protein-43 mRNA in rat dorsal root ganglion during the development of chronic neuropathic painZhonghua Yi Xue Za Zhi2012927444447[PubMed][Google Scholar]
42. PascaleAGusevPAAmadioMIncrease of the RNA-binding protein HuD and posttranscriptional up-regulation of the GAP-43 gene during spatial memoryProc Natl Acad Sci U S A2004101512171222[PubMed][Google Scholar]
43. McIlvainVARobertsonDRMaimoneMMAbnormal thalamocortical pathfinding and terminal arbors lead to enlarged barrels in neonatal GAP-43 heterozygous miceJ Comp Neurol20034622252264[PubMed][Google Scholar]
44. AndersonKDSenguptaJMorinMOverexpression of HuD accelerates neurite outgrowth and increases GAP-43 mRNA expression in cortical neurons and retinoic acid-induced embryonic stem cells in vitroExp Neurol20011682250258[PubMed][Google Scholar]
45. MendonçaHRAraújoSEGomesALExpression of GAP-43 during development and after monocular enucleation in the rat superior colliculusNeurosci Lett201047712327[PubMed][Google Scholar]
46. TolnerEAVlietEAHoltmaatAJGAP-43 mRNA and protein expression in the hippocampal and parahippocampal region during the course of epileptogenesis in ratsEur Neurosci2003171123692380[Google Scholar]
47. MasonMRLiebermanARAndersonPNCorticospinal neurons up-regulate a range of growth-associated genes following intracortical, but not spinal, axotomyEur Neurosci2003184789802[Google Scholar]
48. BenowitzLRouttenbergAGAP-43: an intrinsic determinant of neuronal development and plasticityTrends Neurosci19972028491[PubMed][Google Scholar]
49. SjögrenMMinthonLDavidssonPCSF levels of tau, β-amyloid(1–42) and GAP-43 in frontotemporal dementia, other types of dementia and normal agingJ Neural Transm20001075563579[PubMed][Google Scholar]
50. EastwoodSLHarrisonPJSynaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexinsBrain Res Bull2001555569578[PubMed][Google Scholar]
51. DubroffJGStevensRTHittJAnomalous functional organization of barrel cortex in GAP-43 deficient miceNeuroimage200629410401048[PubMed][Google Scholar]
52. DonovanSLMamounasLAAndrewsAMGAP-43 is critical for normal development of the serotonergic innervation in forebrainJ Neurosci200222935433552[PubMed][Google Scholar]
53. BiewengaJESchramaLHGispenWHPresynaptic phosphoprotein B-50/ GAP-43 in neuronal and synaptic plasticityActa Biochim Pol1996432327338[PubMed][Google Scholar]
54. AignerLArberSKapfhammerJPOverexpression of the neural growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic miceCell1995832269278[PubMed][Google Scholar]
55. VanselowJGrabczykEPingJGAP-43 transgenic mice: dispersed genomic sequences confer a GAP-43-like expression pattern during development and regenerationJ Neurosci1994142499510[PubMed][Google Scholar]
56. ShainDHHaileDTVerrastroTACloning and embryonic expression of Xenopus laevis GAP-43(XGAP-43)Brain Res19956971-2241246[PubMed][Google Scholar]
57. HeQDentEWMeiriKFModulation of actin filament behavior by GAP-43 (Neuromodulin) is dependent on the phosphorylation status of serine41, the protein kinase C siteJ Neurosci1997171035153524[PubMed][Google Scholar]
58. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals2006930
59. HuangJHHuangXHChenZYDose conversion among different animals and healthy volunteers in pharmacological studyZhong Guo Lin Chuang Yao Li Xue Yu Zhi Liao Xue20049910691072[Google Scholar]
60. CaoJLiLSLiuBActivation of growth-associated protein by intragastric brazilein in motor neuron of spinal cord connected with injured sciatic nerve in miceChem Res Chin Univ2011272254257[Google Scholar]